Shots:
The US FDA has approved Atebrioz (100mg, PO, QD) tablets to reduce the volume of total new heterotopic ossification (HO) in pts (≥12yrs.) with FOP, & issued a Rare Pediatric Disease PRV to Incyte. MAA is under EMA’s review
Approval was based on Cohort 1 of the P-II (PROGRESS) study, where at Wk. 24,…
